New arthritis drug shows promise in major trial

NCT ID NCT06738719

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an injectable drug called CT-P13 in 192 adults with moderate-to-severe rheumatoid arthritis. The goal was to see if it reduces joint pain and swelling better than a placebo. Participants received either the drug or a dummy shot, and researchers measured improvement after 12 weeks using standard arthritis scores.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Klinika Reuma Park Sp. z.o.o

    Warsaw, 02-665, Poland